But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
ApexOnco Front Page
Recent articles
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
